BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 28214203)

  • 1. Prognostic value of survivin and DNA topoisomerase IIα in diffuse and anaplastic astrocytomas.
    Varughese RK; Skjulsvik AJ; Torp SH
    Pathol Res Pract; 2017 Apr; 213(4):339-347. PubMed ID: 28214203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hsp27 and its expression pattern in diffusely infiltrating astrocytomas.
    Mäkelä KS; Haapasalo JA; Ilvesaro JM; Parkkila S; Paavonen T; Haapasalo HK
    Histol Histopathol; 2014 Sep; 29(9):1161-8. PubMed ID: 24599602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitosin and pHH3 predict poorer survival in astrocytomas WHO grades II and III.
    Varughese RK; Lind-Landström T; Habberstad AH; Salvesen Ø; Haug CS; Sundstrøm S; Torp SH
    J Clin Pathol; 2016 Jan; 69(1):26-34. PubMed ID: 26188054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.
    Hartmann C; Hentschel B; Wick W; Capper D; Felsberg J; Simon M; Westphal M; Schackert G; Meyermann R; Pietsch T; Reifenberger G; Weller M; Loeffler M; von Deimling A
    Acta Neuropathol; 2010 Dec; 120(6):707-18. PubMed ID: 21088844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IDH1 mutations in diffusely infiltrating astrocytomas: grade specificity, association with protein expression, and clinical relevance.
    Thota B; Shukla SK; Srividya MR; Shwetha SD; Arivazhagan A; Thennarasu K; Chickabasaviah YT; Hegde AS; Chandramouli BA; Somasundaram K; Santosh V
    Am J Clin Pathol; 2012 Aug; 138(2):177-84. PubMed ID: 22904127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KPNA2 predicts long term survival in patients with anaplastic oligoastrocytomas.
    Gousias K; Niehusmann P; Gielen G; Simon M; Boström J
    J Clin Neurosci; 2014 Oct; 21(10):1719-24. PubMed ID: 24929863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IDH1/2 gene hotspot mutations in central nervous system tumours: analysis of 922 Chinese patients.
    Chen N; Yu T; Gong J; Nie L; Chen X; Zhang M; Xu M; Tan J; Su Z; Zhong J; Zhou Q
    Pathology; 2016 Dec; 48(7):675-683. PubMed ID: 27780605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiological and pathological features associated with IDH1-R132H mutation status and early mortality in newly diagnosed anaplastic astrocytic tumours.
    Wasserman JK; Nicholas G; Yaworski R; Wasserman AM; Woulfe JM; Jansen GH; Chakraborty S; Nguyen TB
    PLoS One; 2015; 10(4):e0123890. PubMed ID: 25849605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathological Significance of the Proliferation Markers Ki67, RacGAP1, and Topoisomerase 2 Alpha in Breast Cancer.
    Şahin S; Işık Gönül İ; Çakır A; Seçkin S; Uluoğlu Ö
    Int J Surg Pathol; 2016 Oct; 24(7):607-13. PubMed ID: 27284123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of BCAT1 Expression is a Sensitive Marker for IDH-Mutant Diffuse Glioma.
    Chen YY; Ho HL; Lin SC; Hsu CY; Ho DM
    Neurosurgery; 2019 Sep; 85(3):335-342. PubMed ID: 30113684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prognostic role of IDH mutations in homogeneously treated patients with anaplastic astrocytomas and glioblastomas.
    Christians A; Adel-Horowski A; Banan R; Lehmann U; Bartels S; Behling F; Barrantes-Freer A; Stadelmann C; Rohde V; Stockhammer F; Hartmann C
    Acta Neuropathol Commun; 2019 Oct; 7(1):156. PubMed ID: 31623667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. WT1 expression increases with malignancy and indicates unfavourable outcome in astrocytoma.
    Rauscher J; Beschorner R; Gierke M; Bisdas S; Braun C; Ebner FH; Schittenhelm J
    J Clin Pathol; 2014 Jul; 67(7):556-61. PubMed ID: 24607494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. WT1 Clone 6F-H2 Cytoplasmic Expression Differentiates Astrocytic Tumors from Astrogliosis and Associates with Tumor Grade, Histopathology, IDH1 Status, Apoptotic and Proliferative Indices: A Tissue Microarray Study.
    Abd El-Hafez A; Ismail Hany HSED
    Asian Pac J Cancer Prev; 2020 Aug; 21(8):2403-2413. PubMed ID: 32856872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PROX1 is a novel pathway-specific prognostic biomarker for high-grade astrocytomas; results from independent glioblastoma cohorts stratified by age and IDH mutation status.
    Roodakker KR; Elsir T; Edqvist PD; Hägerstrand D; Carlson J; Lysiak M; Henriksson R; Pontén F; Rosell J; Söderkvist P; Stupp R; Tchougounova E; Nistér M; Malmström A; Smits A
    Oncotarget; 2016 Nov; 7(45):72431-72442. PubMed ID: 27626492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphorylated Hsp27 is mutually exclusive with ATRX loss and the IDH1
    Cai HQ; Wang PF; Zhang HP; Cheng ZJ; Li SW; He J; Zhang Y; Hao JJ; Wang MR; Yan CX; Wan JH
    J Clin Pathol; 2018 Aug; 71(8):702-707. PubMed ID: 29550762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.
    Hartmann C; Meyer J; Balss J; Capper D; Mueller W; Christians A; Felsberg J; Wolter M; Mawrin C; Wick W; Weller M; Herold-Mende C; Unterberg A; Jeuken JW; Wesseling P; Reifenberger G; von Deimling A
    Acta Neuropathol; 2009 Oct; 118(4):469-74. PubMed ID: 19554337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. No prognostic value of IDH1 mutations in a series of 100 WHO grade II astrocytomas.
    Ahmadi R; Stockhammer F; Becker N; Hohlen K; Misch M; Christians A; Dictus C; Herold-Mende C; Capper D; Unterberg A; von Deimling A; Wick W; Hartmann C
    J Neurooncol; 2012 Aug; 109(1):15-22. PubMed ID: 22528790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid progression to glioblastoma in a subset of IDH-mutated astrocytomas: a genome-wide analysis.
    Richardson TE; Snuderl M; Serrano J; Karajannis MA; Heguy A; Oliver D; Raisanen JM; Maher EA; Pan E; Barnett S; Cai C; Habib AA; Bachoo RM; Hatanpaa KJ
    J Neurooncol; 2017 May; 133(1):183-192. PubMed ID: 28421459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T1 high-grade bladder carcinoma outcome: the role of p16, topoisomerase-IIα, survivin, and E-cadherin.
    Raspollini MR; Luque RJ; Menendez CL; Bollito E; Brunelli M; Martignoni G; Montironi R; Cheng L; Blanca A; Baroni G; Minervini A; Lopez-Beltran A
    Hum Pathol; 2016 Nov; 57():78-84. PubMed ID: 27473264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IDH1 mutation in pediatric gliomas: has it a diagnostic and prognostic value?
    Buccoliero AM; Castiglione F; Degl'Innocenti DR; Gheri CF; Genitori L; Taddei GL
    Fetal Pediatr Pathol; 2012 Oct; 31(5):278-82. PubMed ID: 22432788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.